WHWK
WhitehawkยทNASDAQ
--
--(--)
--
--(--)
WHWK Profile
Whitehawk Therapeutics, Inc.
A biopharmaceutical company focused on precision therapies for genetically defined cancers with alterations in mTOR pathway genes
2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey 07960
--
Whitehawk Therapeutics, Inc., was incorporated in Delaware on November 16, 2007. The company is a clinical-stage biopharmaceutical company developing precision therapies for genetically defined cancers. The company's main goal is to bring translational therapies to cancer patients with changes in mTOR pathway drivers, such as changes in the TSC1 or TSC2 genes, while mTOR inhibitors are not or cannot be effectively utilized due to pharmacological, effective drug delivery, safety or efficacy issues. Aadi's main product is FYARROTM, an mTOR inhibitor that binds to human proteins and shows higher tumor accumulation, greater mTOR target inhibition and enhanced tumor growth inhibition.
